Cargando…
Profile of neratinib and its potential in the treatment of breast cancer
The HER (ErbB) receptor tyrosine kinase receptors are implicated in many cancers and several anti-HER treatments are now approved. In recent years, a new group of compounds that bind irreversibly to the adenosine triphosphate binding pocket of HER receptors have been developed. One of these compound...
Autores principales: | Feldinger, Katharina, Kong, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467661/ https://www.ncbi.nlm.nih.gov/pubmed/26089701 http://dx.doi.org/10.2147/BCTT.S54414 |
Ejemplares similares
-
Neratinib for breast cancer
Publicado: (2019) -
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU
por: Dhillon, Sohita
Publicado: (2019) -
Correction to: Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU
por: Dhillon, Sohita
Publicado: (2019) -
Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
por: Miles, Jennifer, et al.
Publicado: (2018) -
Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)